Search Result

Results for "

diastolic pressure

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (4) AMPK (1) Angiotensin-converting Enzyme (ACE) (1) Calcium Channel (5) Calmodulin (1) Drug Derivative (1) Endogenous Metabolite (3) Isotope-Labeled Compounds (1) Melanocortin Receptor (1) NO Synthase (2) SOD (1)
By Research Areas:	Cardiovascular Disease (13) Endocrinology (1) Inflammation/Immunology (1) Metabolic Disease (6) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B2209

Hydroxocobalamin 3 Publications Verification Vitamin B12a	Endogenous Metabolite	Neurological Disease Metabolic Disease
Hydroxocobalamin (Vitamin B12a) is a cyanide antidote. Hydroxocobalamin can decrease the cell and plasma cyanide concentrations and increase survival rate in acute cyanide poisoning. Hydroxocobalamin can improve newborn Cbl-C defect-induced metabolic profile and neurocognitive outcome. Hydroxocobalamin can normalize Vitamin B₁₂ deficiency. Hydroxocobalamin can induce acute kidney injury. Hydroxocobalamin can be used for the researches of metabolic and neurological disease .

HY-W005255

3-(3-Hydroxyphenyl)propionic acid	Endogenous Metabolite	Cardiovascular Disease
3-(3-Hydroxyphenyl)propionic acid (3HPPA) is an endothelium-dependent nitric oxide (NO) release promoter and endothelial nitric oxide synthase (eNOS) activator. 3-(3-Hydroxyphenyl)propionic acid activates eNOS to mediate vascular smooth muscle relaxation and enhances endothelial cell NO synthesis, inducing vasodilation and reducing peripheral vascular resistance. 3-(3-Hydroxyphenyl)propionic acid can dose-dependently reduce systolic and diastolic blood pressure in spontaneously hypertensive rats (SHR) without affecting cardiac contractility or heart rate. 3-(3-Hydroxyphenyl)propionic acid has antihypertensive and vascular protective effects and can be used in the prevention and treatment of cardiovascular diseases .

HY-118060

Dipeptide 2 N-Valyltryptophan; Val-Trp	Angiotensin-converting Enzyme (ACE) Calcium Channel NO Synthase	Cardiovascular Disease
Dipeptide 2 (N-Valyltryptophan) is an orally active, competitive angiotensin-converting enzyme (ACE) inhibitory peptide with an IC₅₀ of 10.50 μM. Dipeptide 2 reduces intracellular Calcium ions. Dipeptide 2 significantly increases the content of NO, inhibits the production of ET-1, and induces the phosphorylation of eNOS. Dipeptide 2 decreases the systolic and diastolic blood pressure of spontaneously hypertensive rats .

HY-19870C

Setmelanotide monoacetate 5+ Cited Publications RM-493 monoacetate; BIM-22493 monoacetate; IRC-022493 monoacetate	Melanocortin Receptor Calmodulin AMPK	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Setmelanotide monoacetate (RM-493 monoacetate) is a blood-brain barrier-permeable, selective MC4R agonist with a K_i value of 2.1 nM for hMC4R. Setmelanotide monoacetate activates the CaMKK2/AMPK signaling pathway. Setmelanotide monoacetate mediates body weight homeostasis, feeding regulation and energy expenditure modulation; it reduces food intake, induces weight loss, decreases obesity severity, increases daytime activity and energy expenditure, lowers levels of leptin, triglycerides, fasting insulin and diastolic blood pressure, improves insulin sensitivity, glucose tolerance and fatty liver condition, and reverses respiratory depression. Setmelanotide monoacetate is applicable to research related to obesity, hyperinsulinemia, fatty liver and respiratory depression .

HY-19664

Pranidipine OPC-13340	Calcium Channel NO Synthase	Cardiovascular Disease
Pranidipine (OPC-13340) is an orally active L-type voltage-dependent calcium channel (L-VDCC) blocker with a K_i value of 0.16 nM. Pranidipine inhibits calcium-induced contraction, suppresses slow-response action potentials, shortens action potential duration, reduces systolic and diastolic blood pressure, and exerts vasodilatory effects. Pranidipine enhances its vasodilatory effect by blocking NO decomposition. Pranidipine can be used in research related to essential hypertension, angina pectoris, myocardial infarction, and dilated cardiomyopathy .

HY-123268A

Ro 363 hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Ro 363 hydrochloride, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. Ro 363 hydrochloride is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility .

HY-123268

Ro 363	Adrenergic Receptor	Cardiovascular Disease
Ro 363, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. RO 363 is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility .

HY-122215

Tilisolol hydrochloride N-696	Adrenergic Receptor	Endocrinology
Tilisolol hydrochloride (N-696) is a non-selective β-adrenergic antagonist with vasodilatory and hypotensive activities. Tilisolol hydrochloride exerts its effects in canine coronary arteries by opening ATP-sensitive K+ channels. Tilisolol hydrochloride exhibits concentration-dependent relaxation in KCl-precontracted rat thoracic aorta. Tilisolol hydrochloride reduces diastolic blood pressure in a dose-dependent manner and slightly increases heart rate in spinal cord stimulated rats .

HY-Z7733

O-Desmethylcarvedilol Desmethylcarvedilol; BM-14242	Calcium Channel	Metabolic Disease
O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of the non-selective β-adrenergic receptor (β-AR) antagonist Carvedilol (HY-B0006). O-Desmethylcarvedilol inhibits store-overload-induced calcium release in HEK293 cells expressing the ryanodine receptor 2 (RyR2) R4496C (RyR2 ^R4496C) mutation (IC₅₀ = 7.62 µM). O-Desmethylcarvedilol reduces increases in heart rate and prevents decreases in diastolic blood pressure induced by Isoproterenol (HY-B0468) in conscious rabbits (ED₅₀s = 32 and 5 µg/kg, respectively) .

HY-W416440

Esmolol acid hydrochloride ASL-8123 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease
Esmolol acid (ASL-8123) hydrochloride is a weak β-adrenergic receptor antagonist. Esmolol acid hydrochloride inhibits the heart rate and diastolic blood pressure response induced by Isoproterenol (HY-B0468) in a dose-dependent manner and can be used in studies of renal failure .

HY-N1115

Tubotaiwine (+)-Tubotaiwine; NSC 306222; Tubotaiwin	Others	Cardiovascular Disease
Tubotaiwine ((+)-Tubotaiwine), an alkaloid, has beneficial effect on cadmium (Cd) induced hypertension in rats. Tubotaiwine regulates systolic, diastolic and mean arterial blood pressure of the Cd exposed rats. Tubotaiwine reduces arterial stiffness, inhibits of oxidative stress and increases vascular remodeling .

HY-129782

SC-55858	SOD	Cardiovascular Disease
SC-55858 is an effective superoxide dismutase simulator. SC-55858 increased heart rate and decreased mean arterial pressure and left ventricular systolic and end-diastolic pressures in conscious dogs .

HY-129706

LY127210 free base	Others	Cardiovascular Disease
LY127210 (free base) is a potent vasodilator with antihypertensive effects that reduces pressure in chloralose-anesthetized spontaneously hypertensive rats primarily by direct arteriolar dilation and to a lesser extent by decreasing cardiac output. LY127210 (free base) reduces blood pressure, heart rate and left ventricular end-diastolic pressure in hypertensive rats by reducing vascular resistance .

HY-101390B

Niguldipine	Calcium Channel	Cardiovascular Disease
Niguldipine is a calcium channel blocker with activity in regulating cardiovascular function. Niguldipine can reduce systolic and diastolic blood pressure, thereby increasing heart rate and cardiac output. Niguldipine exhibits dose-dependent and sustained increases in coronary blood flow. Niguldipine also increases perfusion in the kidneys and femoral arteries, but the effect is temporary and to a lesser extent. The effect of Niguldipine on myocardial metabolism is not significant .

HY-166478S

O-Desmethyl carvedilol-d5 Desmethylcarvedilol-d₅; BM-14242-d₅	Isotope-Labeled Compounds Calcium Channel	Metabolic Disease
O-Desmethyl carvedilol-d₅ (Desmethylcarvedilol-d₅) is deuterium labeled O-Desmethylcarvedilol. O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of the non-selective β-adrenergic receptor (β-AR) antagonist Carvedilol (HY-B0006). O-Desmethylcarvedilol inhibits store-overload-induced calcium release in HEK293 cells expressing the ryanodine receptor 2 (RyR2) R4496C (RyR2 ^R4496C) mutation (IC₅₀ = 7.62 μM). O-Desmethylcarvedilol reduces increases in heart rate and prevents decreases in diastolic blood pressure induced by Isoproterenol (HY-B0468) in conscious rabbits (ED₅₀s = 32 and 5 μg/kg, respectively) .

HY-111259

Ro 31-1118 free base	Endogenous Metabolite	Cardiovascular Disease
Ro 31-1118 Free base is a compound exhibiting weak antihypertensive activity in patients with mild hypertension. Ro 31-1118 Free base demonstrated a reduction in heart rates and blood pressure post-exercise at varying doses. Ro 31-1118 Free base exhibited linear pharmacokinetics within the 10-80 mg dose range. Ro 31-1118 Free base showed no significant impact on diastolic blood pressure or adverse effects during the study.

HY-W343043

Pyrazinoylguanidine PZG	Drug Derivative	Cardiovascular Disease Metabolic Disease
Pyrazinoylguanidine (PZG) is an analogue of the potassium sparing diuretic, Amiloride (HY-B0285). Pyrazinoylguanidine can lower the systolic and diastolic blood pressure of patients with primary hypertension, has a certain effect on reducing heart rate, and does not affect the concentrations of electrolytes such as sodium, potassium, and chloride in the blood serum. Pyrazinoylguanidine can reduce the hyperglycemia and hyperinsulinemia in type 2 diabetes, reduce the levels of triglycerides, cholesterol, and free fatty acids, and reverse the hyperglycemia and hyperlipidemia induced by thiazide diuretics, such as Hydrochlorothiazide (HY-B0252). Pyrazinoylguanidine ican nhibit the reabsorption of urea by the renal tubules, thereby increasing the clearance rate and excretion volume of urea, reducing the serum urea concentration, and minimizing its toxic accumulation .

Cat. No.	Product Name	Target	Research Area

HY-118060

Dipeptide 2 N-Valyltryptophan; Val-Trp	Angiotensin-converting Enzyme (ACE) Calcium Channel NO Synthase	Cardiovascular Disease
Dipeptide 2 (N-Valyltryptophan) is an orally active, competitive angiotensin-converting enzyme (ACE) inhibitory peptide with an IC₅₀ of 10.50 μM. Dipeptide 2 reduces intracellular Calcium ions. Dipeptide 2 significantly increases the content of NO, inhibits the production of ET-1, and induces the phosphorylation of eNOS. Dipeptide 2 decreases the systolic and diastolic blood pressure of spontaneously hypertensive rats .

HY-19870C

Setmelanotide monoacetate 5+ Cited Publications RM-493 monoacetate; BIM-22493 monoacetate; IRC-022493 monoacetate	Melanocortin Receptor Calmodulin AMPK	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Setmelanotide monoacetate (RM-493 monoacetate) is a blood-brain barrier-permeable, selective MC4R agonist with a K_i value of 2.1 nM for hMC4R. Setmelanotide monoacetate activates the CaMKK2/AMPK signaling pathway. Setmelanotide monoacetate mediates body weight homeostasis, feeding regulation and energy expenditure modulation; it reduces food intake, induces weight loss, decreases obesity severity, increases daytime activity and energy expenditure, lowers levels of leptin, triglycerides, fasting insulin and diastolic blood pressure, improves insulin sensitivity, glucose tolerance and fatty liver condition, and reverses respiratory depression. Setmelanotide monoacetate is applicable to research related to obesity, hyperinsulinemia, fatty liver and respiratory depression .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B2209

Hydroxocobalamin 3 Publications Verification Vitamin B12a	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Hydroxocobalamin (Vitamin B12a) is a cyanide antidote. Hydroxocobalamin can decrease the cell and plasma cyanide concentrations and increase survival rate in acute cyanide poisoning. Hydroxocobalamin can improve newborn Cbl-C defect-induced metabolic profile and neurocognitive outcome. Hydroxocobalamin can normalize Vitamin B₁₂ deficiency. Hydroxocobalamin can induce acute kidney injury. Hydroxocobalamin can be used for the researches of metabolic and neurological disease .

HY-W005255

3-(3-Hydroxyphenyl)propionic acid	Cardiovascular Disease Monophenols Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Phenols Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
3-(3-Hydroxyphenyl)propionic acid (3HPPA) is an endothelium-dependent nitric oxide (NO) release promoter and endothelial nitric oxide synthase (eNOS) activator. 3-(3-Hydroxyphenyl)propionic acid activates eNOS to mediate vascular smooth muscle relaxation and enhances endothelial cell NO synthesis, inducing vasodilation and reducing peripheral vascular resistance. 3-(3-Hydroxyphenyl)propionic acid can dose-dependently reduce systolic and diastolic blood pressure in spontaneously hypertensive rats (SHR) without affecting cardiac contractility or heart rate. 3-(3-Hydroxyphenyl)propionic acid has antihypertensive and vascular protective effects and can be used in the prevention and treatment of cardiovascular diseases .

HY-N1115

Tubotaiwine (+)-Tubotaiwine; NSC 306222; Tubotaiwin	Apocynaceae Alkaloids Other Alkaloids Hunteria zeylanica Plants Source Classification	Others
Tubotaiwine ((+)-Tubotaiwine), an alkaloid, has beneficial effect on cadmium (Cd) induced hypertension in rats. Tubotaiwine regulates systolic, diastolic and mean arterial blood pressure of the Cd exposed rats. Tubotaiwine reduces arterial stiffness, inhibits of oxidative stress and increases vascular remodeling .

Cat. No.	Product Name	Chemical Structure

HY-166478S

O-Desmethyl carvedilol-d5
O-Desmethyl carvedilol-d₅ (Desmethylcarvedilol-d₅) is deuterium labeled O-Desmethylcarvedilol. O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of the non-selective β-adrenergic receptor (β-AR) antagonist Carvedilol (HY-B0006). O-Desmethylcarvedilol inhibits store-overload-induced calcium release in HEK293 cells expressing the ryanodine receptor 2 (RyR2) R4496C (RyR2 ^R4496C) mutation (IC₅₀ = 7.62 μM). O-Desmethylcarvedilol reduces increases in heart rate and prevents decreases in diastolic blood pressure induced by Isoproterenol (HY-B0468) in conscious rabbits (ED₅₀s = 32 and 5 μg/kg, respectively) .

O-Desmethyl carvedilol-d5

O-Desmethyl carvedilol-d₅ (Desmethylcarvedilol-d₅) is deuterium labeled O-Desmethylcarvedilol. O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of the non-selective β-adrenergic receptor (β-AR) antagonist Carvedilol (HY-B0006). O-Desmethylcarvedilol inhibits store-overload-induced calcium release in HEK293 cells expressing the ryanodine receptor 2 (RyR2) R4496C (RyR2 ^R4496C) mutation (IC₅₀ = 7.62 μM). O-Desmethylcarvedilol reduces increases in heart rate and prevents decreases in diastolic blood pressure induced by Isoproterenol (HY-B0468) in conscious rabbits (ED₅₀s = 32 and 5 μg/kg, respectively) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

diastolic pressure

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products